Samsung Biologics Co Ltd (207940) — Long-term Investment Intensity

Latest as of December 2018: 43.2%

Samsung Biologics Co Ltd (207940) has a Long-term Investment Intensity of 43.2% as of December 2018. Long-term investments of ₩2.59 Trillion represent 43.2% of total assets of ₩5.98 Trillion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See Samsung Biologics Co Ltd (207940) shareholders funds for net asset value and shareholders' equity analysis.

LT Investment Intensity

43.2%
LT Investments / Total Assets

Long-term Investments

₩2.59 Trillion
KRW

Total Assets

₩5.98 Trillion
KRW

Country

Korea
KO

Samsung Biologics Co Ltd Long-term Investment Intensity (2014–2018)

This chart shows how Samsung Biologics Co Ltd's Long-term Investment Intensity has evolved across 5 annual periods from 2014 to 2018. As of December 2018, the intensity stands at 43.2%, reflecting long-term investments of ₩2.59 Trillion against total assets of ₩5.98 Trillion KRW. Also explore total assets of Samsung Biologics Co Ltd for the complete picture of this company's asset base.

Annual Long-term Investment Intensity for Samsung Biologics Co Ltd (2014–2018)

The table below presents the year-by-year Long-term Investment Intensity for Samsung Biologics Co Ltd from 2014 to 2018, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see 207940 market cap overview.

Year LT Investment Intensity LT Investments (KRW) Total Assets Change (pp)
2018 43.2% ₩2.59 Trillion ₩5.98 Trillion ▼ -26.5 pp
2017 69.7% ₩5.01 Trillion ₩7.18 Trillion ▲ +4.1 pp
2016 65.6% ₩4.94 Trillion ₩7.53 Trillion ▼ -15.5 pp
2015 81.2% ₩4.84 Trillion ₩5.96 Trillion ▲ +77.2 pp
2014 4.0% ₩53.92 Billion ₩1.36 Trillion
pp = percentage points